Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism CD39 inhibitors(Ectonucleoside triphosphate diphosphohydrolase 1 inhibitors), ICOS antagonists(Inducible T-cell costimulator antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Mozart Therapeutics, Inc.Startup |
Active Organization Mozart Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | US | Mozart Therapeutics, Inc.Startup | 08 Feb 2024 |